EUVIMEDEUVIMED entdecken
Open Access

BLAST: A Globally Applicable and Molecularly Versatile Survival Model for Chronic Myelomonocytic Leukemia

Ayalew Tefferi, Saubia Fathima iD, Maymona Abdelmagid, Ali Khalid A Alsugair, Fnu Aperna, Mahsa Rezasoltani, Muhammad Yousuf, Anuya Natu, Clifford M Csizmar iD, Mark Gurney, Terra L Lasho, Christy M Finke und 23 weitere

Blood Journal · 07.05.2025

DOI: 10.1182/blood.2024027170 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood Journal, online erschienen am 07.05.2025. Verfasst von Ayalew Tefferi und 34 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic, Rochester, MN. Hauptthemen laut MEDLINE: Leukemia, Myelomonocytic, Chronic, Blast Crisis. Die Arbeit wurde bisher 23-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We sought to develop a survival model in chronic myelomonocytic leukemia (CMML) that is primarily based on clinical variables and examine additional impact from mutations and karyotype. 457 molecularly-annotated patients were considered. Multivariable analysis identified circulating Blasts ≥2% (1 point), Leukocytes ≥13 x 109/L (1 point), and severe (2 points) or moderate (1 point) Anemia as preferred risk variables in developing a clinical risk Stratification Tool for overall survival (OS), acronymized to "BLAST": low-risk (0 points; median 63 months); intermediate-risk (1 point; median 28 months; HR 2.2, 95% CI 1.6-3.0), and high-risk (2-4 points; median 13 months; 5.4, 4.1-7.3); the corresponding 3/5 year OS rates were 68%/53%, 43%/18%, and 12%/1%. BLAST model performance (AUC 0.77/0.85 at 3/5-years) was shown to be comparable to that of the molecular CMML-specific prognostic scoring system (CMML-mol; AUC 0.73/0.75) and the international prognostic scoring system-molecular (IPSS-M; AUC 0.73/0.74). Multivariable analysis of mutations and karyotype identified PHF6MUT and TET2MUT as being "favorable" and DNMT3AMUT, U2AF1MUT, BCORMUT, SETBP1MUT, ASXL1MUT, NRASMUT, PTPN11MUT, RUNX1MUT, TP53MUT, and adverse karyotype, "unfavorable". Molecular information was subsequently encoded in a combined clinical-molecular risk model (BLAST-mol; AUC 0.80/0.86 at 3/5-years) that included the aforementioned BLAST clinical risk variables and a 3-tiered molecular risk score. BLAST and BLAST-mol were subsequently validated by two separate external cohorts. Independent risk factors for blast transformation included DNMT3AMUT, ASXL1MUT, PHF6WT, leukocytes ≥13 x 109/L, and ≥2% circulating or ≥10% bone marrow blasts. The current study proposes an easy to implement, globally applicable, and molecularly adaptive risk model for CMML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelomonocytic, ChronicBlast CrisisHumansFemaleMaleAgedMiddle AgedAged, 80 and overMutationAdultPrognosisSurvival Rate

Autor:innen und Institutionen

  • Division of Hematology, Mayo Clinic, Rochester, MN.
  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
  • Dipartimento di Oncologia ed Onco-Ematologia, Università degli Studi di Milano, Milan, Italy.
  • Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.
  • Hematology and Bone Marrow Transplant Center, Azienda Socio Sanitaria Territoriale Fatebenefratelli-Sacco, Università degli Studi di Milano, Milan, Italy.

ORCID-Profile: Saubia Fathima, Clifford M Csizmar, Rashmi Kangal-Shamanna, Danielle Hammond, Kelly Chien, Courtney D DiNardo, Naval Daver, Rong He, Sanam Loghavi, Koji Sasaki, Dirk R Larson, Francesco Onida, Naseema Gangat, Mrinal M Patnaik

Förderung

  • NCI NIH HHS

Zitieren

APA

Tefferi, A., Fathima, S., Abdelmagid, M., Alsugair, A. K. A., Aperna, F., Rezasoltani, M., Yousuf, M., Natu, A., Csizmar, C. M., Gurney, M., Lasho, T. L., Finke, C. M., Kangal-Shamanna, R., Hammond, D., Chien, K., Bazinet, A., DiNardo, C. D., Kadia, T. M., Mangaonkar, A. A., …, & Patnaik, M. M. (2025). BLAST: A Globally Applicable and Molecularly Versatile Survival Model for Chronic Myelomonocytic Leukemia. Blood Journal. https://doi.org/10.1182/blood.2024027170

Vancouver

Tefferi A, Fathima S, Abdelmagid M, Alsugair AKA, Aperna F, Rezasoltani M, et al. BLAST: A Globally Applicable and Molecularly Versatile Survival Model for Chronic Myelomonocytic Leukemia. Blood Journal. 2025. doi:10.1182/blood.2024027170

BibTeX
@article{Tefferi2025,
  author = {Tefferi, Ayalew and Fathima, Saubia and Abdelmagid, Maymona and Alsugair, Ali Khalid A and Aperna, Fnu and Rezasoltani, Mahsa and Yousuf, Muhammad and Natu, Anuya and Csizmar, Clifford M and Gurney, Mark and Lasho, Terra L and Finke, Christy M and Kangal-Shamanna, Rashmi and Hammond, Danielle and Chien, Kelly and Bazinet, Alexandre and DiNardo, Courtney D and Kadia, Tapan M and Mangaonkar, Abhishek A and Daver, Naval and Pardanani, Animesh and Borthakur, Gautam and Zepeda-Mendoza, Cinthya and Reichard, Kaaren K and He, Rong and Loghavi, Sanam and Passamonti, Francesco and Ravandi, Farhad and Sasaki, Koji and Larson, Dirk R and Garcia-Manero, Guillermo and Onida, Francesco and Gangat, Naseema and Montalban-Bravo, Guillermo and Patnaik, Mrinal M},
  title = {BLAST: A Globally Applicable and Molecularly Versatile Survival Model for Chronic Myelomonocytic Leukemia},
  journal = {Blood Journal},
  year = {2025},
  doi = {10.1182/blood.2024027170}
}
Kostenlos starten →